Sigma Planning Corp Has $238,000 Holdings in uniQure (NASDAQ:QURE)

Sigma Planning Corp trimmed its position in uniQure (NASDAQ:QURE) by 51.6% in the third quarter, Holdings Channel reports. The fund owned 48,245 shares of the biotechnology company’s stock after selling 51,460 shares during the quarter. Sigma Planning Corp’s holdings in uniQure were worth $238,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the company. Vanguard Group Inc. raised its position in uniQure by 11.4% in the first quarter. Vanguard Group Inc. now owns 1,072,536 shares of the biotechnology company’s stock valued at $5,577,000 after purchasing an additional 109,740 shares during the last quarter. Acadian Asset Management LLC increased its stake in shares of uniQure by 133.1% in the first quarter. Acadian Asset Management LLC now owns 613,490 shares of the biotechnology company’s stock valued at $3,189,000 after buying an additional 350,291 shares during the period. Covestor Ltd raised its holdings in uniQure by 103.2% in the 1st quarter. Covestor Ltd now owns 53,690 shares of the biotechnology company’s stock valued at $279,000 after buying an additional 27,267 shares during the last quarter. Carlson Capital L P boosted its position in uniQure by 16.6% during the 1st quarter. Carlson Capital L P now owns 227,400 shares of the biotechnology company’s stock worth $1,182,000 after buying an additional 32,400 shares during the period. Finally, Ikarian Capital LLC grew its holdings in uniQure by 198.1% during the 1st quarter. Ikarian Capital LLC now owns 469,133 shares of the biotechnology company’s stock worth $2,439,000 after acquiring an additional 311,768 shares during the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on QURE shares. Royal Bank of Canada dropped their price target on shares of uniQure from $16.00 to $14.00 and set an “outperform” rating for the company in a research note on Wednesday, November 6th. The Goldman Sachs Group lowered their target price on uniQure from $10.00 to $9.00 and set a “neutral” rating for the company in a research report on Wednesday, November 6th. StockNews.com upgraded uniQure to a “sell” rating in a research report on Thursday, October 17th. HC Wainwright restated a “buy” rating and set a $25.00 price objective on shares of uniQure in a research report on Wednesday, November 6th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $28.00 price objective on shares of uniQure in a research note on Wednesday, November 6th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $17.00.

uniQure Price Performance

uniQure stock opened at $6.21 on Friday. The stock has a market capitalization of $302.43 million, a price-to-earnings ratio of -1.25 and a beta of 0.90. uniQure has a 52-week low of $3.73 and a 52-week high of $11.35. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51. The stock’s 50 day moving average price is $5.89 and its two-hundred day moving average price is $5.90.

uniQure (NASDAQ:QURE) last issued its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.12) by $0.21. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. The business had revenue of $2.29 million for the quarter, compared to analyst estimates of $2.73 million. On average, equities analysts predict that uniQure will post -3.81 earnings per share for the current year.

uniQure Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.